View Item 

Show simple item record

Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice
dc.contributor.authorO’Brien, Phillipe D.
dc.contributor.authorHinder, Lucy M.
dc.contributor.authorParlee, Sebastian D.
dc.contributor.authorHayes, John M.
dc.contributor.authorBackus, Carey
dc.contributor.authorZhang, Hongyu
dc.contributor.authorMa, Lijun
dc.contributor.authorSakowski, Stacey A.
dc.contributor.authorBrosius, Frank C.
dc.contributor.authorFeldman, Eva L.
dc.date.accessioned2017-10-05T18:17:09Z
dc.date.available2019-01-07T18:34:36Zen
dc.date.issued2017-10
dc.identifier.citationO’Brien, Phillipe D.; Hinder, Lucy M.; Parlee, Sebastian D.; Hayes, John M.; Backus, Carey; Zhang, Hongyu; Ma, Lijun; Sakowski, Stacey A.; Brosius, Frank C.; Feldman, Eva L. (2017). "Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice." Diabetes, Obesity and Metabolism 19(10): 1468-1472.
dc.identifier.issn1462-8902
dc.identifier.issn1463-1326
dc.identifier.urihttps://hdl.handle.net/2027.42/138252
dc.publisherWiley Periodicals, Inc.
dc.publisherBlackwell Publishing Ltd
dc.subject.otherdiabetes complications
dc.subject.otherdiabetic nephropathy
dc.subject.othermouse model
dc.subject.otherdiabetic neuropathy
dc.subject.otheranimal pharmacology
dc.subject.otherdrug mechanism
dc.titleDual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138252/1/dom12950.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138252/2/dom12950_am.pdf
dc.identifier.doi10.1111/dom.12950
dc.identifier.sourceDiabetes, Obesity and Metabolism
dc.identifier.citedreferenceNavarro‐Gonzalez JF, Mora‐Fernandez C, Muros de Fuentes M, Garcia‐Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011; 7: 327 ‐ 340.
dc.identifier.citedreferenceHotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860 ‐ 867.
dc.identifier.citedreferenceNadkarni GN, Yacoub R, Coca SG. Update on glycemic control for the treatment of diabetic kidney disease. Curr Diab Rep. 2015; 15: 42.
dc.identifier.citedreferenceCallaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012 6: CD007543.
dc.identifier.citedreferenceWilson NM, Wright DE. Inflammatory mediators in diabetic neuropathy. J Diabetes Metab. 2011;( suppl 5 ): 004.
dc.identifier.citedreferenceWang W, Poole B, Mitra A, et al. Role of leptin deficiency in early acute renal failure during endotoxemia in ob/ob mice. J Am Soc Nephrol. 2004; 15: 645 ‐ 649.
dc.identifier.citedreferenceHudkins KL, Pichaiwong W, Wietecha T, et al. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol. 2010; 21: 1533 ‐ 1542.
dc.identifier.citedreferenceO’Brien PD, Hur J, Hayes JM, Backus C, Sakowski SA, Feldman EL. BTBR ob/ob mice as a novel diabetic neuropathy model: neurological characterization and gene expression analyses. Neurobiol Dis. 2014; 73: 348 ‐ 355.
dc.identifier.citedreferenceRuster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci. 2008; 13: 944 ‐ 955.
dc.identifier.citedreferencede Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140‐B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 2015; 3: 687 ‐ 696.
dc.identifier.citedreferenceKang YS, Lee MH, Song HK, et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int. 2010; 78: 883 ‐ 894.
dc.identifier.citedreferenceSullivan TJ, Miao Z, Zhao BN, et al. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism. 2013; 62: 1623 ‐ 1632.
dc.identifier.citedreferenceDoupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009; 94: 2157 ‐ 2163.
dc.identifier.citedreferenceHerder C, Bongaerts BW, Rathmann W, et al. Differential association between biomarkers of subclinical inflammation and painful polyneuropathy: results from the KORA F4 study. Diabetes Care. 2015; 38: 91 ‐ 96.
dc.identifier.citedreferenceNguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton). 2006; 11: 226 ‐ 231.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
dom12950.pdf
Size:
1.227MB
Format:
PDF
View/Open
Name:
dom12950_am.pdf
Size:
1.177MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.